The health benefits of tea varieties from Camellia sinensis
PEARL (University of Plymouth) · 08.08.2024
DOI: 10.24382/e9nf-xv30 ↗Kurz gefasst
Fachartikel in der Zeitschrift PEARL (University of Plymouth), erschienen am 08.08.2024. Verfasst von Taylerson und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background and aims: Varieties of tea from the plant Camellia sinensis have been consumed for around 50 centuries and today are a popular beverage worldwide. Over the past 30 years much research has gone into the medicinal properties and health benefits that these teas provide consumers. This review aims to consolidate the benefits of tea’s antioxidant and antimicrobial properties and evaluate the research to this date.
Methods
This review plans to use the primary literature available from journals and online sources found using search engines. Most recent literature will be used primarily, as well as that from 10-20 years ago for history, and studies using cohorts.
Conclusions
Catechins from non-fermented varieties have both antimicrobial and antioxidant activities which offer protection from cancers, cardiovascular diseases and dental caries. Varieties of fermented teas, namely black tea, where catechins have been converted into thearubigins and theaflavins, have antimicrobial and antioxidant potential but to less of an extent. It is apparent however, that less research using black tea has been done relative to that of green.
Schlagwörter
Zitieren
APA
Taylerson, & Katie (2024). The health benefits of tea varieties from Camellia sinensis. PEARL (University of Plymouth). https://doi.org/10.24382/e9nf-xv30
Vancouver
Taylerson, Katie. The health benefits of tea varieties from Camellia sinensis. PEARL (University of Plymouth). 2024. doi:10.24382/e9nf-xv30
BibTeX
@article{Taylerson2024,
author = {Taylerson and Katie},
title = {The health benefits of tea varieties from Camellia sinensis},
journal = {PEARL (University of Plymouth)},
year = {2024},
doi = {10.24382/e9nf-xv30}
}
EUVIMED